Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older Individuals
Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3,...
Saved in:
| Published in | PloS one Vol. 7; no. 6; p. e34078 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
11.06.2012
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0034078 |
Cover
Loading…
| Abstract | Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort.
664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique.
At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years.
Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. |
|---|---|
| AbstractList | Objectives Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort. Methods 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. Results At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E [epsilon]4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years. Conclusions Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. Objectives Apolipoproteins have recently been implicated in the etiology of Alzheimer’s disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort. Methods 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. Results At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years. Conclusions Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort. 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years. Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort.664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique.At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years.Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort. 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E [epsilon]4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years. Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. Objectives Apolipoproteins have recently been implicated in the etiology of Alzheimer’s disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort. Methods 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. Results At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years. Conclusions Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort.OBJECTIVESApolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort.664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique.METHODS664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique.At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years.RESULTSAt Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years.Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals.CONCLUSIONSElderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals. |
| Audience | Academic |
| Author | Smythe, George A. Cameron, Barbara Kochan, Nicole A. Sachdev, Perminder S. Lux, Ora Brodaty, Henry Wen, Wei Poljak, Anne Crawford, John Mather, Karen Song, Fei |
| AuthorAffiliation | 4 School of Medical Sciences, University of New South Wales, Sydney, Australia 1 Brain and Aging Research Program, University of New South Wales, Sydney, Australia 5 Dementia Collaborative Research Centre, University of New South Wales, Sydney, Australia 2 School of Psychiatry, University of New South Wales, Sydney, Australia Nathan Kline Institute and New York University School of Medicine, United States of America 3 Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, Australia |
| AuthorAffiliation_xml | – name: 1 Brain and Aging Research Program, University of New South Wales, Sydney, Australia – name: 4 School of Medical Sciences, University of New South Wales, Sydney, Australia – name: 5 Dementia Collaborative Research Centre, University of New South Wales, Sydney, Australia – name: 3 Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, Australia – name: Nathan Kline Institute and New York University School of Medicine, United States of America – name: 2 School of Psychiatry, University of New South Wales, Sydney, Australia |
| Author_xml | – sequence: 1 givenname: Fei surname: Song fullname: Song, Fei – sequence: 2 givenname: Anne surname: Poljak fullname: Poljak, Anne – sequence: 3 givenname: John surname: Crawford fullname: Crawford, John – sequence: 4 givenname: Nicole A. surname: Kochan fullname: Kochan, Nicole A. – sequence: 5 givenname: Wei surname: Wen fullname: Wen, Wei – sequence: 6 givenname: Barbara surname: Cameron fullname: Cameron, Barbara – sequence: 7 givenname: Ora surname: Lux fullname: Lux, Ora – sequence: 8 givenname: Henry surname: Brodaty fullname: Brodaty, Henry – sequence: 9 givenname: Karen surname: Mather fullname: Mather, Karen – sequence: 10 givenname: George A. surname: Smythe fullname: Smythe, George A. – sequence: 11 givenname: Perminder S. surname: Sachdev fullname: Sachdev, Perminder S. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22701550$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tuEzEQhleoiB7gDRBYQkJwkeDDrnfDBVJUTpEiBVHg1ppd24krr53a3tC-PQ5Nq6aqENoLW7Pf_894NHNcHDjvVFE8J3hMWE3enfshOLDjdQ6PMWYlrptHxRGZMDriFLODO_fD4jjGc4wr1nD-pDiktMakqvBRcfnNQuwBTdfemrVfB5-UcWiuNspGNA0KTWP0nYGkJPpt0gqd-qUzyWwUOkuQhojASfRRddY4hbIUMtH3Q2au8m3lQ0Jeo4WVKqCZk2Zj5AA2Pi0e63yoZ7vzpPj5-dOP06-j-eLL7HQ6H3V8QtNISgqkpIp2XMqmAg6lgqputcRkQrXkTVvJuuVlk0Fdcc5b0E3HSkmgJDWwk-Llte_a-ih2TYuCMFphWhNCMjG7JqSHc7EOpodwJTwY8Tfgw1JASKazStSKaEVU2dDJtqgJNAxK3baUc61LYNnrwy7b0PZKdsqlAHbPdP-PMyux9BvBWJ0LmmSDNzuD4C8GFZPoTeyUteCUH3LdmOKGEU6bjL66hz78uh21hPwA47TPebutqZiWdUYqxstMjR-g8idVb7o8Ydrk-J7g7Z4gM0ldpiUMMYrZ2ff_Zxe_9tnXd9iVAptW0dshGe_iPvjibqdvW3wz2hkor4Eu-BiD0rcIwWK7QTftEtsNErsNyrL392SdyXOe0-eOGPtv8R-ezCJM |
| CitedBy_id | crossref_primary_10_1039_D1FO01471D crossref_primary_10_1186_s12991_021_00376_w crossref_primary_10_3390_genes10030227 crossref_primary_10_1016_j_neurobiolaging_2014_04_022 crossref_primary_10_1159_000368982 crossref_primary_10_1007_s12035_022_02762_1 crossref_primary_10_1055_s_0044_1795115 crossref_primary_10_1186_s13195_023_01294_7 crossref_primary_10_1111_ene_13074 crossref_primary_10_1016_j_neurobiolaging_2019_02_017 crossref_primary_10_1080_13811118_2022_2111533 crossref_primary_10_1002_pmic_201700279 crossref_primary_10_3389_fneur_2019_00879 crossref_primary_10_3389_fnins_2023_1275932 crossref_primary_10_1016_j_pnpbp_2019_109792 crossref_primary_10_1016_j_neurobiolaging_2017_02_017 crossref_primary_10_1038_tp_2014_114 crossref_primary_10_1186_s13024_023_00684_7 crossref_primary_10_3390_ijms252111701 crossref_primary_10_3233_JAD_150036 crossref_primary_10_1016_j_jalz_2013_10_007 crossref_primary_10_1002_gps_4145 crossref_primary_10_1016_j_jgo_2013_09_001 crossref_primary_10_1016_j_jpsychires_2022_04_002 crossref_primary_10_1007_s11357_024_01462_z crossref_primary_10_1016_j_dadm_2016_06_005 crossref_primary_10_1016_j_jagp_2015_06_004 crossref_primary_10_1016_j_jagp_2015_12_005 crossref_primary_10_1186_s12917_021_02744_w crossref_primary_10_3233_JAD_150286 crossref_primary_10_1016_j_neuropharm_2017_06_026 crossref_primary_10_1177_1533317513505133 crossref_primary_10_1016_j_mad_2015_03_009 crossref_primary_10_1371_journal_pone_0116920 crossref_primary_10_33549_physiolres_933121 crossref_primary_10_3390_antiox9050456 crossref_primary_10_1097_MD_0000000000029906 crossref_primary_10_3233_JAD_160913 crossref_primary_10_3390_neurosci3010002 crossref_primary_10_1590_1980_57642018dn13_010002 crossref_primary_10_14283_jpad_2024_34 crossref_primary_10_3390_ijms242417415 crossref_primary_10_1096_fj_201903128RR crossref_primary_10_1155_2015_481621 crossref_primary_10_4103_0366_6999_225062 crossref_primary_10_1371_journal_pone_0089041 crossref_primary_10_1016_j_addr_2020_10_006 crossref_primary_10_3389_fneur_2021_660212 crossref_primary_10_3390_ijms241713064 crossref_primary_10_1016_j_jconrel_2021_08_018 crossref_primary_10_7554_eLife_58954 crossref_primary_10_1016_j_jalz_2017_01_008 crossref_primary_10_1021_acs_biomac_9b01650 crossref_primary_10_1186_alzrt235 crossref_primary_10_1016_j_jprot_2022_104507 crossref_primary_10_3390_cells12030385 crossref_primary_10_1111_jnc_15170 crossref_primary_10_1007_s11011_018_0325_0 crossref_primary_10_1002_alz_14224 crossref_primary_10_3390_cells11061030 crossref_primary_10_1136_bmjopen_2021_054347 crossref_primary_10_1007_s00702_013_1036_7 crossref_primary_10_1186_1471_2164_15_199 crossref_primary_10_1016_j_jprot_2015_05_039 crossref_primary_10_1371_journal_pone_0187364 crossref_primary_10_1186_s12974_023_02850_6 crossref_primary_10_3389_fneur_2015_00236 crossref_primary_10_1002_ajmg_b_32509 crossref_primary_10_1002_mds_28362 crossref_primary_10_1007_s12035_015_9440_7 crossref_primary_10_1111_cns_12707 crossref_primary_10_1212_WNL_0000000000007574 crossref_primary_10_1016_j_smrv_2018_08_001 crossref_primary_10_1038_s41598_017_12858_7 crossref_primary_10_1186_1477_5956_12_5 crossref_primary_10_1016_j_dadm_2018_11_003 crossref_primary_10_1002_alz_14038 crossref_primary_10_1016_j_neuropsychologia_2015_09_031 crossref_primary_10_1016_j_dadm_2014_11_005 crossref_primary_10_18632_aging_203161 crossref_primary_10_2174_1381612826666200218101818 crossref_primary_10_3233_JAD_160206 crossref_primary_10_1016_j_bbapap_2013_04_007 crossref_primary_10_3390_ijms20061394 crossref_primary_10_3389_fnagi_2014_00154 crossref_primary_10_3390_biom10091276 crossref_primary_10_1080_00207454_2017_1286654 crossref_primary_10_3389_fphar_2021_700587 crossref_primary_10_1186_s13195_016_0231_9 crossref_primary_10_1371_journal_pone_0181719 crossref_primary_10_1186_s12888_019_2174_8 crossref_primary_10_3390_jcm13082361 crossref_primary_10_1021_acs_jproteome_6b00998 crossref_primary_10_1159_000520081 crossref_primary_10_1016_j_sleep_2015_01_004 crossref_primary_10_3389_fnagi_2021_696944 crossref_primary_10_1002_agm2_70008 crossref_primary_10_3390_antiox10030454 crossref_primary_10_1007_s00401_014_1266_2 crossref_primary_10_1038_s41531_025_00888_2 crossref_primary_10_1002_biof_1541 crossref_primary_10_3390_ijms22083933 crossref_primary_10_3233_JAD_200291 crossref_primary_10_1371_journal_pone_0179280 crossref_primary_10_1016_j_eclinm_2022_101695 crossref_primary_10_3233_JAD_190524 crossref_primary_10_1016_j_nbd_2014_07_015 crossref_primary_10_2147_NDT_S238985 crossref_primary_10_1186_s13195_023_01203_y crossref_primary_10_3233_JAD_181096 crossref_primary_10_1111_nan_12248 crossref_primary_10_3389_fphar_2015_00278 crossref_primary_10_1016_j_dadm_2018_07_001 crossref_primary_10_3389_fnagi_2018_00409 crossref_primary_10_1016_j_neurobiolaging_2017_04_002 crossref_primary_10_1038_srep23675 crossref_primary_10_1080_01616412_2017_1281195 crossref_primary_10_1159_000477847 crossref_primary_10_1186_s40345_019_0159_7 crossref_primary_10_3233_JAD_220050 crossref_primary_10_3233_JAD_210403 crossref_primary_10_1371_journal_pone_0214141 crossref_primary_10_3233_JAD_151068 crossref_primary_10_1002_gps_4245 crossref_primary_10_1016_j_jalz_2017_11_012 crossref_primary_10_1093_ijnp_pyae029 crossref_primary_10_14283_jpad_2019_50 crossref_primary_10_3389_fnagi_2023_1274794 crossref_primary_10_3233_JAD_150537 crossref_primary_10_1186_s12014_018_9207_z crossref_primary_10_3233_JAD_160457 crossref_primary_10_1111_ejn_16392 crossref_primary_10_3109_09540261_2013_860890 crossref_primary_10_3389_fnagi_2019_00100 crossref_primary_10_3233_JAD_180849 |
| Cites_doi | 10.1037/0894-4105.21.1.1 10.1159/000313978 10.1136/bmj.322.7300.1447 10.1212/01.WNL.0000149519.47454.F2 10.1016/j.neuint.2005.12.005 10.1016/S0197-4580(99)00103-7 10.1097/CRD.0b013e3181c4b508 10.1016/S1568-9972(01)00005-2 10.1016/j.atherosclerosis.2009.09.072 10.1023/A:1007516210548 10.1038/ng.439 10.1001/archneurol.2010.215 10.1111/j.1600-0404.1999.tb00724.x 10.1212/WNL.43.8.1467 10.1016/0022-3956(75)90026-6 10.1016/S0304-3940(98)00339-5 10.1021/bi00474a025 10.1212/01.WNL.0000132523.27540.81 10.1161/CIRCULATIONAHA.107.699579 10.1016/S0006-8993(01)02222-3 10.1111/j.1365-2796.2004.01388.x 10.1038/sj.mp.4001854 10.1194/jlr.M800155-JLR200 10.1016/j.jns.2009.02.004 10.1016/j.neurobiolaging.2009.02.007 10.1212/WNL.0b013e318211c352 10.1515/CCLM.2000.102 10.1001/archneur.58.12.1985 10.1016/S0022-2275(20)41208-8 10.1007/s11064-008-9588-x 10.1016/0009-8981(95)06115-T 10.1042/bj2930027 10.1001/jama.1995.03520400044042 10.1073/pnas.93.9.4229 10.1159/000017045 10.1016/S0304-3940(97)00429-1 10.1038/nbt.1622 10.1212/01.WNL.0000160114.42643.31 10.1016/j.neurobiolaging.2009.07.015 10.1097/JGP.0b013e3180547053 10.3233/JAD-2011-111088 10.1016/j.pcad.2009.06.005 10.3109/13547500903108423 10.1002/pmic.200300495 10.1182/blood-2005-05-1943 10.1038/ng.440 10.1111/j.1365-2796.2004.01380.x 10.1159/000323417 10.1017/S0007114509992194 10.1007/s004010050815 10.1111/j.2517-6161.1995.tb02031.x 10.1006/bbrc.1998.9652 10.1093/aje/155.6.487 10.1001/archgenpsychiatry.2010.78 10.1212/WNL.43.11.2412-a 10.1006/exnr.1998.6892 10.1212/01.wnl.0000228244.10416.20 10.1159/000110800 10.1111/j.1471-4159.2009.06408.x 10.1159/000090676 10.1007/s00415-003-0142-0 10.1007/s00418-009-0567-3 10.1001/archneur.62.5.753 10.1021/pr7006329 10.1016/S0304-3940(98)00381-4 10.1007/BF00296787 10.1159/000051195 10.1016/j.neurobiolaging.2010.04.028 10.1074/jbc.M110.127829 10.1097/00041433-200406000-00002 10.1016/j.brainresrev.2009.05.007 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 Public Library of Science 2012 Song et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Song et al. 2012 |
| Copyright_xml | – notice: COPYRIGHT 2012 Public Library of Science – notice: 2012 Song et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Song et al. 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0034078 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Acceso a contenido Full Text - Doaj |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine Biology |
| DocumentTitleAlternate | Plasma Apolipoprotein and Cognitive Decline |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1325027111 oai_doaj_org_article_7e1fe1e4829142e9a83a4fbb266ff4a3 PMC3372509 2940456031 A477115364 22701550 10_1371_journal_pone_0034078 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Sydney New South Wales Australia Australia |
| GeographicLocations_xml | – name: Sydney New South Wales Australia – name: Australia |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RIG RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB PV9 RZL BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c692t-dd2a142e2c6dd85a6a4ea57bfd0192fd68b5d7b648d2af5666baf8c34d1a417a3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:17:46 EST 2021 Wed Aug 27 01:30:08 EDT 2025 Thu Aug 21 18:29:31 EDT 2025 Fri Sep 05 12:21:10 EDT 2025 Fri Jul 25 10:13:33 EDT 2025 Tue Jun 17 20:36:31 EDT 2025 Tue Jun 10 20:41:04 EDT 2025 Fri Jun 27 04:40:56 EDT 2025 Fri Jun 27 04:54:41 EDT 2025 Thu May 22 21:23:15 EDT 2025 Mon Jul 21 05:50:12 EDT 2025 Thu Apr 24 22:53:57 EDT 2025 Tue Jul 01 01:20:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-dd2a142e2c6dd85a6a4ea57bfd0192fd68b5d7b648d2af5666baf8c34d1a417a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: FS AP PS. Performed the experiments: FS KM. Analyzed the data: FS KM. Contributed reagents/materials/analysis tools: FS JC NK WW BC OL. Wrote the paper: FS AP JC NK BC HB GS PS. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0034078 |
| PMID | 22701550 |
| PQID | 1325027111 |
| PQPubID | 1436336 |
| PageCount | e34078 |
| ParticipantIDs | plos_journals_1325027111 doaj_primary_oai_doaj_org_article_7e1fe1e4829142e9a83a4fbb266ff4a3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3372509 proquest_miscellaneous_1020831628 proquest_journals_1325027111 gale_infotracmisc_A477115364 gale_infotracacademiconefile_A477115364 gale_incontextgauss_ISR_A477115364 gale_incontextgauss_IOV_A477115364 gale_healthsolutions_A477115364 pubmed_primary_22701550 crossref_primary_10_1371_journal_pone_0034078 crossref_citationtrail_10_1371_journal_pone_0034078 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-06-11 |
| PublicationDateYYYYMMDD | 2012-06-11 |
| PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-11 day: 11 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2012 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | JE Eichner (ref16) 2002; 155 IJ Martins (ref61) 2009; 111 TL Lewis (ref18) 2010; 285 R Scacchi (ref25) 1998; 9 C Dufouil (ref13) 2005; 64 D Harold (ref39) 2009; 41 RB D'Agostino Sr (ref52) 2008; 117 YM Kuo (ref59) 1998; 252 (ref1) 2010 HV de Silva (ref67) 1990; 29 RC Petersen (ref2) 2004; 256 A Alonso (ref11) 2009; 280 C Sihlbom (ref76) 2008; 33 IJ Martins (ref12) 2006; 11 A Ohrfelt (ref38) 2011; 1 EJ Laukka (ref8) 2010; 29 J Millan (ref15) 2009; 5 B de Laat (ref63) 2006; 107 TC Jordan-Starck (ref68) 1994; 35 M Lindh (ref36) 1997; 229 VB Gupta (ref54) 2011; 76 M Kawano (ref21) 1995; 239 G Siest (ref31) 2000; 38 JC Lambert (ref40) 2009; 41 S Kullberg (ref74) 2001; 899 I Hindmarch (ref47) 1998; 9 RC Petersen (ref27) 1995; 273 Y Benjamini (ref53) 1995; 57 T Darreh-Shori (ref35) 2011; 32 PS Sachdev (ref42) 2010 P Caramelli (ref23) 1999; 100 RC Petersen (ref4) 2001; 58 R Takechi (ref60) 2009; 131 DL Sparks (ref14) 2005; 62 (ref46) 1994 AE Roher (ref57) 2009 E Bereczki (ref22) 2008; 7 MS Leduc (ref37) 2008; 49 A Merched (ref56) 2000; 21 SD Rountree (ref5) 2007; 24 A Katzav (ref19) 2011; 32 M Thambisetty (ref20) 2010; 67 VB Gupta (ref29) 2011; 76 A Castro (ref64) 2010; 209 B Winblad (ref45) 2004; 256 T Nuutinen (ref41) 2009; 61 KA Jellinger (ref7) 2003; 250 JC Morris (ref48) 1993; 43 RA Whitmer (ref10) 2005; 64 PA Boyle (ref6) 2006; 67 T Darreh-Shori (ref34) 2011 M Ganguli (ref3) 2004; 63 T Pirttila (ref30) 1998; 249 AF Jorm (ref49) 2007; 21 AM Saunders (ref28) 1993; 43 AJ Slooter (ref32) 1998; 248 P Giannakopoulos (ref73) 1998; 95 J Ghiso (ref70) 1993; 1 SE O’Bryant (ref51) 2010; 67 M Kivipelto (ref9) 2001; 322 R Zhang (ref24) 2004; 4 C Hesse (ref33) 2000; 25 D George (ref65) 2009; 52 HC Liu (ref55) 2006; 21 TM Anderson (ref44) 2007; 15 AM Nilselid (ref75) 2006; 48 G Ruiz-Irastorza (ref66) 2002; 1 KW van Dijk (ref26) 2004; 15 MF Folstein (ref43) 1975; 12 T Darreh-Shori (ref62) 2011; 28 R Takechi (ref17) 2010; 103 BV Zlokovic (ref71) 1996; 93 (ref50); 28 NH Choi-Miura (ref69) 1992; 83 AM Lidstrom (ref72) 1998; 154 CB Sherman (ref58) 2010; 18 16786033 - Mol Psychiatry. 2006 Aug;11(8):721-36 20523048 - Dement Geriatr Cogn Disord. 2010;29(6):498-503 12849057 - Autoimmun Rev. 2002 Feb;1(1-2):43-8 15883313 - Neurology. 2005 May 10;64(9):1531-8 11735772 - Arch Neurol. 2001 Dec;58(12):1985-92 15668425 - Neurology. 2005 Jan 25;64(2):277-81 20847045 - J Biol Chem. 2010 Nov 19;285(47):36958-68 15324362 - J Intern Med. 2004 Sep;256(3):183-94 17545447 - Am J Geriatr Psychiatry. 2007 Jun;15(6):467-76 9223597 - Neurosci Lett. 1997 Jun 27;229(2):85-8 9672379 - Neurosci Lett. 1998 Jun 12;249(1):21-4 20603455 - Arch Gen Psychiatry. 2010 Jul;67(7):739-48 22163231 - Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):31-42 1974459 - Biochemistry. 1990 Jun 5;29(22):5380-9 22012848 - J Alzheimers Dis. 2012;28(2):443-58 20395699 - Cardiol Rev. 2010 May-Jun;18(3):141-7 17992015 - Dement Geriatr Cogn Disord. 2007;24(6):476-82 19734903 - Nat Genet. 2009 Oct;41(10):1094-9 20637138 - Int Psychogeriatr. 2010 Dec;22(8):1248-64 14504965 - J Neurol. 2003 Sep;250(9):1050-5 9878186 - Exp Neurol. 1998 Dec;154(2):511-21 19225804 - Histochem Cell Biol. 2009 May;131(5):661-6 19774217 - Vasc Health Risk Manag. 2009;5:757-65 20050287 - J Neurochem. 2009 Dec;111(6):1275-308 10416513 - Acta Neurol Scand. 1999 Jul;100(1):61-3 18676959 - J Lipid Res. 2008 Dec;49(12):2648-56 15166778 - Curr Opin Lipidol. 2004 Jun;15(3):239-46 14730686 - Proteomics. 2004 Jan;4(1):244-56 11071064 - Clin Chem Lab Med. 2000 Aug;38(8):721-30 19251275 - J Neurol Sci. 2009 May 15;280(1-2):79-83 18212285 - Circulation. 2008 Feb 12;117(6):743-53 11882522 - Am J Epidemiol. 2002 Mar 15;155(6):487-95 11408299 - BMJ. 2001 Jun 16;322(7300):1447-51 9560017 - Acta Neuropathol. 1998 Apr;95(4):387-94 19713000 - Neurobiol Aging. 2011 Jul;32(7):1236-48 8542660 - Clin Chim Acta. 1995 Aug 14;239(2):209-11 9718231 - Dement Geriatr Cogn Disord. 1998;9 Suppl 2:20-6 1373021 - Acta Neuropathol. 1992;83(3):260-4 9681639 - Dement Geriatr Cogn Disord. 1998 Jul-Aug;9(4):186-90 8350998 - Neurology. 1993 Aug;43(8):1467-72 8169523 - J Lipid Res. 1994 Feb;35(2):194-210 15249620 - Neurology. 2004 Jul 13;63(1):115-21 11311878 - Brain Res. 2001 Apr 27;899(1-2):169-86 19282067 - Neurobiol Aging. 2011 Feb;32(2):272-9 16894105 - Neurology. 2006 Aug 8;67(3):441-5 1202204 - J Psychiatr Res. 1975 Nov;12(3):189-98 20538374 - Neurobiol Aging. 2011 Dec;32(12):2320.e15-32 19651157 - Brain Res Rev. 2009 Oct;61(2):89-104 19732604 - Prog Cardiovasc Dis. 2009 Sep-Oct;52(2):115-25 16269621 - Blood. 2006 Mar 1;107(5):1916-24 8232972 - Neurology. 1993 Nov;43(11):2412-4 19860996 - Br J Nutr. 2010 Mar;103(5):652-62 20837851 - Arch Neurol. 2010 Sep;67(9):1077-81 21422459 - Neurology. 2011 Mar 22;76(12):1091-8 17201525 - Neuropsychology. 2007 Jan;21(1):1-8 10794845 - Neurobiol Aging. 2000 Jan-Feb;21(1):27-30 15883262 - Arch Neurol. 2005 May;62(5):753-7 8633046 - Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4229-34 20458316 - Nat Biotechnol. 2010 May;28(5):463-9 19878946 - Atherosclerosis. 2010 Mar;209(1):201-5 19734902 - Nat Genet. 2009 Oct;41(10):1088-93 9837771 - Biochem Biophys Res Commun. 1998 Nov 27;252(3):711-5 19863188 - Biomarkers. 2009 Nov;14(7):493-501 18288611 - Neurochem Res. 2008 Jul;33(7):1332-40 8328966 - Biochem J. 1993 Jul 1;293 ( Pt 1):27-30 16490286 - Neurochem Int. 2006 Jun;48(8):718-28 16391478 - Dement Geriatr Cogn Disord. 2006;21(3):155-61 15324367 - J Intern Med. 2004 Sep;256(3):240-6 9665654 - Neurosci Lett. 1998 May 22;248(1):21-4 7646655 - JAMA. 1995 Apr 26;273(16):1274-8 18473452 - J Proteome Res. 2008 Jun;7(6):2246-52 10823584 - Neurochem Res. 2000 Apr;25(4):511-7 |
| References_xml | – volume: 5 start-page: 757 year: 2009 ident: ref15 article-title: Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. publication-title: Vasc Health Risk Manag – volume: 21 start-page: 1 year: 2007 ident: ref49 article-title: APOE genotype and cognitive functioning in a large age-stratified population sample. publication-title: Neuropsychology doi: 10.1037/0894-4105.21.1.1 – volume: 29 start-page: 498 year: 2010 ident: ref8 article-title: The influence of vascular disease on cognitive performance in the preclinical and early phases of Alzheimer’s disease. publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000313978 – volume: 322 start-page: 1447 year: 2001 ident: ref9 article-title: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. publication-title: BMJ doi: 10.1136/bmj.322.7300.1447 – volume: 64 start-page: 277 year: 2005 ident: ref10 article-title: Midlife cardiovascular risk factors and risk of dementia in late life. publication-title: Neurology doi: 10.1212/01.WNL.0000149519.47454.F2 – volume: 48 start-page: 718 year: 2006 ident: ref75 article-title: Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. publication-title: Neurochem Int doi: 10.1016/j.neuint.2005.12.005 – volume: 21 start-page: 27 year: 2000 ident: ref56 article-title: Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. publication-title: Neurobiol Aging doi: 10.1016/S0197-4580(99)00103-7 – volume: 18 start-page: 141 year: 2010 ident: ref58 article-title: Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. publication-title: Cardiol Rev doi: 10.1097/CRD.0b013e3181c4b508 – volume: 1 start-page: 43 year: 2002 ident: ref66 article-title: Hughes syndrome crosses boundaries. publication-title: Autoimmun Rev doi: 10.1016/S1568-9972(01)00005-2 – volume: 209 start-page: 201 year: 2010 ident: ref64 article-title: APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2009.09.072 – volume: 25 start-page: 511 year: 2000 ident: ref33 article-title: Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. publication-title: Neurochem Res doi: 10.1023/A:1007516210548 – volume: 41 start-page: 1094 year: 2009 ident: ref40 article-title: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. publication-title: Nat Genet doi: 10.1038/ng.439 – volume: 67 start-page: 1077 year: 2010 ident: ref51 article-title: A serum protein-based algorithm for the detection of Alzheimer disease. publication-title: Arch Neurol doi: 10.1001/archneurol.2010.215 – volume: 100 start-page: 61 year: 1999 ident: ref23 article-title: Increased apolipoprotein B serum concentration in Alzheimer/s disease. publication-title: Acta Neurol Scand doi: 10.1111/j.1600-0404.1999.tb00724.x – volume: 43 start-page: 1467 year: 1993 ident: ref28 article-title: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. publication-title: Neurology doi: 10.1212/WNL.43.8.1467 – volume: 12 start-page: 189 year: 1975 ident: ref43 article-title: “Mini-mental state” publication-title: J Psychiatr Res doi: 10.1016/0022-3956(75)90026-6 – volume: 248 start-page: 21 year: 1998 ident: ref32 article-title: Serum apolipoprotein E level is not increased in Alzheimer’s disease: the Rotterdam study. publication-title: Neurosci Lett doi: 10.1016/S0304-3940(98)00339-5 – volume: 29 start-page: 5380 year: 1990 ident: ref67 article-title: Apolipoprotein J: structure and tissue distribution. publication-title: Biochemistry doi: 10.1021/bi00474a025 – volume: 63 start-page: 115 year: 2004 ident: ref3 article-title: Mild cognitive impairment, amnestic type: an epidemiologic study. publication-title: Neurology doi: 10.1212/01.WNL.0000132523.27540.81 – volume: 117 start-page: 743 year: 2008 ident: ref52 article-title: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.699579 – volume: 899 start-page: 169 year: 2001 ident: ref74 article-title: Microglial activation, emergence of ED1-expressing cells and clusterin upregulation in the aging rat CNS, with special reference to the spinal cord. publication-title: Brain Res doi: 10.1016/S0006-8993(01)02222-3 – volume: 256 start-page: 183 year: 2004 ident: ref2 article-title: Mild cognitive impairment as a diagnostic entity. publication-title: J Intern Med doi: 10.1111/j.1365-2796.2004.01388.x – volume: 11 start-page: 721 year: 2006 ident: ref12 article-title: Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001854 – volume: 49 start-page: 2648 year: 2008 ident: ref37 article-title: Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA. publication-title: J Lipid Res doi: 10.1194/jlr.M800155-JLR200 – volume: 280 start-page: 79 year: 2009 ident: ref11 article-title: Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. publication-title: J Neurol Sci doi: 10.1016/j.jns.2009.02.004 – volume: 32 start-page: 272 year: 2011 ident: ref19 article-title: Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.02.007 – volume: 76 start-page: 1091 year: 2011 ident: ref54 article-title: Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. publication-title: Neurology doi: 10.1212/WNL.0b013e318211c352 – volume: 38 start-page: 721 year: 2000 ident: ref31 article-title: Apolipoprotein E polymorphism and serum concentration in Alzheimer’s disease in nine European centres: the ApoEurope study. ApoEurope group. publication-title: Clin Chem Lab Med doi: 10.1515/CCLM.2000.102 – volume: 58 start-page: 1985 year: 2001 ident: ref4 article-title: Current concepts in mild cognitive impairment. publication-title: Arch Neurol doi: 10.1001/archneur.58.12.1985 – volume: 35 start-page: 194 year: 1994 ident: ref68 article-title: Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. publication-title: J Lipid Res doi: 10.1016/S0022-2275(20)41208-8 – volume: 33 start-page: 1332 year: 2008 ident: ref76 article-title: Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals. publication-title: Neurochem Res doi: 10.1007/s11064-008-9588-x – volume: 239 start-page: 209 year: 1995 ident: ref21 article-title: Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer/s disease. publication-title: Clin Chim Acta doi: 10.1016/0009-8981(95)06115-T – volume: 1) start-page: 27 year: 1993 ident: ref70 article-title: The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. publication-title: Biochem J 293 (Pt doi: 10.1042/bj2930027 – volume: 273 start-page: 1274 year: 1995 ident: ref27 article-title: Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. publication-title: JAMA doi: 10.1001/jama.1995.03520400044042 – volume: 93 start-page: 4229 year: 1996 ident: ref71 article-title: Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.9.4229 – volume: 9 start-page: 186 year: 1998 ident: ref25 article-title: DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer’s disease. publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000017045 – volume: 229 start-page: 85 year: 1997 ident: ref36 article-title: Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer’s disease patients are increased at follow up and show a correlation with levels of tau protein. publication-title: Neurosci Lett doi: 10.1016/S0304-3940(97)00429-1 – volume: 28 start-page: 463 ident: ref50 article-title: Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. publication-title: Nat Biotechnol doi: 10.1038/nbt.1622 – volume: 64 start-page: 1531 year: 2005 ident: ref13 article-title: APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. publication-title: Neurology doi: 10.1212/01.WNL.0000160114.42643.31 – volume: 32 start-page: 1236 year: 2011 ident: ref35 article-title: The apolipoprotein E epsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2009.07.015 – volume: 15 start-page: 467 year: 2007 ident: ref44 article-title: Effects of sociodemographic and health variables on Mini-Mental State Exam scores in older Australians. publication-title: Am J Geriatr Psychiatry doi: 10.1097/JGP.0b013e3180547053 – year: 1994 ident: ref46 article-title: Diagnostic and Statistical Manual of Mental Disorders: American Psychiatric Association. – volume: 28 start-page: 443 year: 2011 ident: ref62 article-title: Apolipoprotein epsilon4 Modulates Phenotype of Butyrylcholinesterase in CSF of Patients with Alzheimer’s Disease. publication-title: J Alzheimers Dis doi: 10.3233/JAD-2011-111088 – volume: 52 start-page: 115 year: 2009 ident: ref65 article-title: Antiphospholipid syndrome. publication-title: Prog Cardiovasc Dis doi: 10.1016/j.pcad.2009.06.005 – year: 2009 ident: ref57 article-title: Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. doi: 10.3109/13547500903108423 – volume: 4 start-page: 244 year: 2004 ident: ref24 article-title: Mining biomarkers in human sera using proteomic tools. publication-title: Proteomics doi: 10.1002/pmic.200300495 – volume: 107 start-page: 1916 year: 2006 ident: ref63 article-title: Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. publication-title: Blood doi: 10.1182/blood-2005-05-1943 – volume: 41 start-page: 1088 year: 2009 ident: ref39 article-title: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. publication-title: Nat Genet doi: 10.1038/ng.440 – volume: 256 start-page: 240 year: 2004 ident: ref45 article-title: Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. publication-title: J Intern Med doi: 10.1111/j.1365-2796.2004.01380.x – volume: 1 start-page: 31 year: 2011 ident: ref38 article-title: Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease. publication-title: Dement Geriatr Cogn Dis Extra doi: 10.1159/000323417 – volume: 103 start-page: 652 year: 2010 ident: ref17 article-title: Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta. publication-title: Br J Nutr doi: 10.1017/S0007114509992194 – volume: 95 start-page: 387 year: 1998 ident: ref73 article-title: Possible neuroprotective role of clusterin in Alzheimer’s disease: a quantitative immunocytochemical study. publication-title: Acta Neuropathol doi: 10.1007/s004010050815 – volume: 57 start-page: 289 year: 1995 ident: ref53 article-title: Controlling the false discovery rate: a practical and powerful approach to multiple testing. publication-title: Jounrnal of the Royal Statistical Society Series B (Methodological) doi: 10.1111/j.2517-6161.1995.tb02031.x – volume: 252 start-page: 711 year: 1998 ident: ref59 article-title: Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain abeta 1–42 levels. publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1998.9652 – volume: 155 start-page: 487 year: 2002 ident: ref16 article-title: Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. publication-title: Am J Epidemiol doi: 10.1093/aje/155.6.487 – volume: 67 start-page: 739 year: 2010 ident: ref20 article-title: Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. publication-title: Arch Gen Psychiatry doi: 10.1001/archgenpsychiatry.2010.78 – volume: 43 start-page: 2412 year: 1993 ident: ref48 article-title: The Clinical Dementia Rating (CDR): current version and scoring rules. publication-title: Neurology doi: 10.1212/WNL.43.11.2412-a – volume: 154 start-page: 511 year: 1998 ident: ref72 article-title: Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. publication-title: Exp Neurol doi: 10.1006/exnr.1998.6892 – volume: 67 start-page: 441 year: 2006 ident: ref6 article-title: Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. publication-title: Neurology doi: 10.1212/01.wnl.0000228244.10416.20 – volume: 24 start-page: 476 year: 2007 ident: ref5 article-title: Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000110800 – volume: 111 start-page: 1275 year: 2009 ident: ref61 article-title: Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease. publication-title: J Neurochem doi: 10.1111/j.1471-4159.2009.06408.x – volume: 21 start-page: 155 year: 2006 ident: ref55 article-title: Proteomic identification of lower apolipoprotein A-I in Alzheimer’s disease. publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000090676 – volume: 250 start-page: 1050 year: 2003 ident: ref7 article-title: The impact of cerebrovascular lesions in Alzheimer disease–a comparative autopsy study. publication-title: J Neurol doi: 10.1007/s00415-003-0142-0 – volume: 131 start-page: 661 year: 2009 ident: ref60 article-title: Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. publication-title: Histochem Cell Biol doi: 10.1007/s00418-009-0567-3 – volume: 62 start-page: 753 year: 2005 ident: ref14 article-title: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. publication-title: Arch Neurol doi: 10.1001/archneur.62.5.753 – volume: 7 start-page: 2246 year: 2008 ident: ref22 article-title: Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. publication-title: J Proteome Res doi: 10.1021/pr7006329 – volume: 249 start-page: 21 year: 1998 ident: ref30 article-title: Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer’s disease. publication-title: Neurosci Lett doi: 10.1016/S0304-3940(98)00381-4 – start-page: 1 year: 2010 ident: ref42 article-title: The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70–90 years. – volume: 83 start-page: 260 year: 1992 ident: ref69 article-title: SP-40,40 is a constituent of Alzheimer’s amyloid. publication-title: Acta Neuropathol doi: 10.1007/BF00296787 – volume: 9 start-page: 20 year: 1998 ident: ref47 article-title: The Bayer Activities of Daily Living Scale (B-ADL). publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000051195 – year: 2010 ident: ref1 article-title: (Alzheimer’s Disease International 2010) World Alzheimer Report – year: 2011 ident: ref34 article-title: Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer’s disease in the brain in vivo. doi: 10.1016/j.neurobiolaging.2010.04.028 – volume: 285 start-page: 36958 year: 2010 ident: ref18 article-title: Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. publication-title: J Biol Chem doi: 10.1074/jbc.M110.127829 – volume: 15 start-page: 239 year: 2004 ident: ref26 article-title: The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? publication-title: Curr Opin Lipidol doi: 10.1097/00041433-200406000-00002 – volume: 76 start-page: 1091 year: 2011 ident: ref29 article-title: Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. publication-title: Neurology doi: 10.1212/WNL.0b013e318211c352 – volume: 61 start-page: 89 year: 2009 ident: ref41 article-title: Clusterin: a forgotten player in Alzheimer’s disease. publication-title: Brain Res Rev doi: 10.1016/j.brainresrev.2009.05.007 – reference: 18676959 - J Lipid Res. 2008 Dec;49(12):2648-56 – reference: 8542660 - Clin Chim Acta. 1995 Aug 14;239(2):209-11 – reference: 22012848 - J Alzheimers Dis. 2012;28(2):443-58 – reference: 16391478 - Dement Geriatr Cogn Disord. 2006;21(3):155-61 – reference: 8633046 - Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4229-34 – reference: 20458316 - Nat Biotechnol. 2010 May;28(5):463-9 – reference: 8232972 - Neurology. 1993 Nov;43(11):2412-4 – reference: 16786033 - Mol Psychiatry. 2006 Aug;11(8):721-36 – reference: 15324362 - J Intern Med. 2004 Sep;256(3):183-94 – reference: 1974459 - Biochemistry. 1990 Jun 5;29(22):5380-9 – reference: 19878946 - Atherosclerosis. 2010 Mar;209(1):201-5 – reference: 9681639 - Dement Geriatr Cogn Disord. 1998 Jul-Aug;9(4):186-90 – reference: 19734902 - Nat Genet. 2009 Oct;41(10):1088-93 – reference: 20538374 - Neurobiol Aging. 2011 Dec;32(12):2320.e15-32 – reference: 15166778 - Curr Opin Lipidol. 2004 Jun;15(3):239-46 – reference: 18473452 - J Proteome Res. 2008 Jun;7(6):2246-52 – reference: 20837851 - Arch Neurol. 2010 Sep;67(9):1077-81 – reference: 16490286 - Neurochem Int. 2006 Jun;48(8):718-28 – reference: 16269621 - Blood. 2006 Mar 1;107(5):1916-24 – reference: 9560017 - Acta Neuropathol. 1998 Apr;95(4):387-94 – reference: 20637138 - Int Psychogeriatr. 2010 Dec;22(8):1248-64 – reference: 8350998 - Neurology. 1993 Aug;43(8):1467-72 – reference: 9837771 - Biochem Biophys Res Commun. 1998 Nov 27;252(3):711-5 – reference: 10794845 - Neurobiol Aging. 2000 Jan-Feb;21(1):27-30 – reference: 12849057 - Autoimmun Rev. 2002 Feb;1(1-2):43-8 – reference: 1202204 - J Psychiatr Res. 1975 Nov;12(3):189-98 – reference: 8328966 - Biochem J. 1993 Jul 1;293 ( Pt 1):27-30 – reference: 17992015 - Dement Geriatr Cogn Disord. 2007;24(6):476-82 – reference: 17201525 - Neuropsychology. 2007 Jan;21(1):1-8 – reference: 9718231 - Dement Geriatr Cogn Disord. 1998;9 Suppl 2:20-6 – reference: 20603455 - Arch Gen Psychiatry. 2010 Jul;67(7):739-48 – reference: 14504965 - J Neurol. 2003 Sep;250(9):1050-5 – reference: 11735772 - Arch Neurol. 2001 Dec;58(12):1985-92 – reference: 15883262 - Arch Neurol. 2005 May;62(5):753-7 – reference: 19732604 - Prog Cardiovasc Dis. 2009 Sep-Oct;52(2):115-25 – reference: 10416513 - Acta Neurol Scand. 1999 Jul;100(1):61-3 – reference: 7646655 - JAMA. 1995 Apr 26;273(16):1274-8 – reference: 16894105 - Neurology. 2006 Aug 8;67(3):441-5 – reference: 18288611 - Neurochem Res. 2008 Jul;33(7):1332-40 – reference: 15883313 - Neurology. 2005 May 10;64(9):1531-8 – reference: 1373021 - Acta Neuropathol. 1992;83(3):260-4 – reference: 15324367 - J Intern Med. 2004 Sep;256(3):240-6 – reference: 19713000 - Neurobiol Aging. 2011 Jul;32(7):1236-48 – reference: 20523048 - Dement Geriatr Cogn Disord. 2010;29(6):498-503 – reference: 9223597 - Neurosci Lett. 1997 Jun 27;229(2):85-8 – reference: 11882522 - Am J Epidemiol. 2002 Mar 15;155(6):487-95 – reference: 15668425 - Neurology. 2005 Jan 25;64(2):277-81 – reference: 11071064 - Clin Chem Lab Med. 2000 Aug;38(8):721-30 – reference: 19734903 - Nat Genet. 2009 Oct;41(10):1094-9 – reference: 19863188 - Biomarkers. 2009 Nov;14(7):493-501 – reference: 19282067 - Neurobiol Aging. 2011 Feb;32(2):272-9 – reference: 19225804 - Histochem Cell Biol. 2009 May;131(5):661-6 – reference: 20395699 - Cardiol Rev. 2010 May-Jun;18(3):141-7 – reference: 21422459 - Neurology. 2011 Mar 22;76(12):1091-8 – reference: 8169523 - J Lipid Res. 1994 Feb;35(2):194-210 – reference: 19251275 - J Neurol Sci. 2009 May 15;280(1-2):79-83 – reference: 11408299 - BMJ. 2001 Jun 16;322(7300):1447-51 – reference: 19860996 - Br J Nutr. 2010 Mar;103(5):652-62 – reference: 22163231 - Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):31-42 – reference: 14730686 - Proteomics. 2004 Jan;4(1):244-56 – reference: 10823584 - Neurochem Res. 2000 Apr;25(4):511-7 – reference: 19651157 - Brain Res Rev. 2009 Oct;61(2):89-104 – reference: 9878186 - Exp Neurol. 1998 Dec;154(2):511-21 – reference: 18212285 - Circulation. 2008 Feb 12;117(6):743-53 – reference: 9665654 - Neurosci Lett. 1998 May 22;248(1):21-4 – reference: 19774217 - Vasc Health Risk Manag. 2009;5:757-65 – reference: 17545447 - Am J Geriatr Psychiatry. 2007 Jun;15(6):467-76 – reference: 15249620 - Neurology. 2004 Jul 13;63(1):115-21 – reference: 9672379 - Neurosci Lett. 1998 Jun 12;249(1):21-4 – reference: 20847045 - J Biol Chem. 2010 Nov 19;285(47):36958-68 – reference: 11311878 - Brain Res. 2001 Apr 27;899(1-2):169-86 – reference: 20050287 - J Neurochem. 2009 Dec;111(6):1275-308 |
| SSID | ssj0053866 |
| Score | 2.460771 |
| Snippet | Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been... Objectives Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has... Objectives Apolipoproteins have recently been implicated in the etiology of Alzheimer’s disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has... Objectives Apolipoproteins have recently been implicated in the etiology of Alzheimer’s disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e34078 |
| SubjectTerms | Activities of daily living Advertising executives Aged Aged, 80 and over Aging Alzheimer's disease Analysis of Variance Apolipoprotein E Apolipoproteins Apolipoproteins - blood Atherosclerosis Atrophy Bioindicators Biology Biomarkers Brain research Carbohydrates Cerebrospinal fluid Cholesterol Clusterin Cognition Cognitive ability Cognitive Dysfunction - blood Cohort Studies Communities Correlation analysis Dementia Dementia disorders Development and progression Etiology Fluorescence Fluoroimmunoassay Geriatrics Glycoproteins Humans Immunoassay Impairment Linear Models Lipids Longitudinal Studies Low density lipoprotein Magnetic resonance imaging Mass spectrometry Medicine Memory Multiplexing Neurodegenerative diseases New South Wales Older people Plasma Predictive control Proteins Psychiatry Rodents Scientific imaging Spinal cord Studies Substantia alba Substantia grisea Triglycerides |
| SummonAdditionalLinks | – databaseName: Acceso a contenido Full Text - Doaj dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZQT1wQy2sLCxiEBByyW8eOnRwXxGpB4iFg0d6icWxDpZJUTSvt_ntmEjdq0ErLgUsPnc99zIzH43bmG8Ze2GJWVEHJxEooEox-OgGHDz7PjDHOVTZQN_LHT_r0TH04z853Rn1RTVhPD9wr7sh4EbzwKk8LoVJfQC5BBWvxYAlBQcfzOStm28tUH4NxF2sdG-WkEUfRLofLpvaHRMkyo7FqOwdRx9c_ROXJctG0V6Wcf1dO7hxFJ7fZrZhD8uP-s--xG76-w_biLm35q0gl_fouu_iCyfFv4ECzGJZNR8owr_mCKoVaDivPIZrHO04_yfKhnIhTq9EGQbXjzlMDpee4FBDRtZSsLzkN112teRN4Q7O--Xxo7mrvsbOTd9_fniZx1kJS6SJdJ86lQPpNK-1cnoEG5SEzNjjKAYPTuc2csVrlCAyYA2oLIa-kcgKUMCDvs0mN2t1nPBcQLGTe5Zg6UOePchXgtWXmLaanRZgyuVV8WUUicpqHsSi7f9cMXkh6PZZkrjKaa8qSYdWyJ-K4Bv-GbDpgiUa7ewKdq4zOVV7nXFP2lDyi7HtSh2BQHitjMJWWWk3Z8w5BVBo11er8hE3blu8___gH0LevI9DLCAoNqqOC2B-B34koukbIgxESA0I1Eu-T_2610qKOMM9NUSpw5danrxY_G8T0olR_V_tmgxia5SqFTlGvD_otMGg2TU130Z0yM9ocI9WPJfX8V8dkLqXB9y4e_g9bPWI3MZlNqYxPiAM2Wa82_jEmjGv7pIsNfwBzYm0b priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLegXLggxtcCGxiEBByy1bFjJydUBmVDwBAwtFtkx_Y2aSTZ0krw3_Ne6oQFTcClqurnpHlf_tl5H4Q8Nfk0L73gseE6j8H7yVhb-HBZqpSytjQes5E_fJS7B-LdYXoYDtzaEFbZ-8TOUdu6xDPybdg1pbCFAtN82ZzF2DUK366GFhpXyTUGKw3qeTZ_23tisGUpQ7ocV2w7SGerqSu3hYVZpthc7cJy1FXtH3zzpDmt28uA55_xkxcWpPlNciMgSTpbiX6NXHHVLbIWbLWlz0NB6Re3yY9PAJG_azrDjgxN3ZVmOKnoe4wXauECjvZCcpbiwSzd6YOKKILRZUt1Zelrh2mUjsJUTUNiyeInfDsGCE9rT_ex4zfdG1K82jvkYP7m685uHDouxKXMk0VsbaKZSFxSSmuzVEstnE6V8RaRoLcyM6lVRooMCD0gQWm0z0ouLNOCKc3vkkkF3F0nNGPaG506mwGAwPwfYUsNm5epMwBScx8R3jO-KEM5cuyKcVp079gUbEtWfCxQXEUQV0TiYVazKsfxD_pXKNOBFotpdz_U50dFsM1COeYdcyJLcnz4XGdcC28MaJT3QvOIPEKNKFaZqYNLKGZCgT6mXIqIPOkosKBGhRE7R3rZtsXe_rf_IPryeUT0LBD5GthR6pAlAc-EhbpGlBsjSnAL5Wh4HfW350pb_DYgmNnr9OXDj4dhvChG4VWuXgINdnTlTCbA13srExg4mySq2-5GRI2MY8T68Uh1ctzVM-dcwb3z-3__Ww_IdQCrCYbpMbZBJovzpdsEQLgwDzur_wX3rmKP priority: 102 providerName: ProQuest |
| Title | Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older Individuals |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22701550 https://www.proquest.com/docview/1325027111 https://www.proquest.com/docview/1020831628 https://pubmed.ncbi.nlm.nih.gov/PMC3372509 https://doaj.org/article/7e1fe1e4829142e9a83a4fbb266ff4a3 http://dx.doi.org/10.1371/journal.pone.0034078 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLa27oUXxLitMIpBSMBDqjpx4uQBoa6sbIhdNCjqW2TH9japJKVppe3fc07qRASVy0tU1ceO_NnH_hyfCyGvVDJIMssDTwUy8WD1izyp4WHiUAihdaYseiOfnEZHE_5pGk63SJ2z1QFYbjzaYT6pyWLWv_lx-x4U_l2VtUGwulJ_XuSmjwFXYNvbJjuwN0V4HDvhzb0CaHd1e4msxYv8QeCc6f7USmuzqmL6Nyt3Zz4ryk209Hfryl-2q_E9ctfxTDpcT4xdsmXy-2TXaXJJ37hw028fkJtzINDfJR1ivoZ5UQVuuM7pZ7QmKqEBQ-shNJriZ1s6qk2OKFLVVUllrukHg06WhkJVSZ3byfIWfl0BtrSw9AzzgdPjxgGsfEgm48OvoyPP5WPwsijxl57WvmTcN34WaR2HMpLcyFAoq5EnWh3FKtRCRTwGQQs8MVLSxlnANZOcCRk8Ip0c0N0jNGbSKhkaHQO9QO8grjMJR5uBUUBhE9slQQ18mrlg5ZgzY5ZWN3ACDi1rHFMcrtQNV5d4Ta35OljHP-QPcEwbWQy1Xf1RLC5Tp7mpMMwaZnjsJ9j5RMaB5FYpYDbWchl0yXOcEenab7VZMNIhFwLodhDxLnlZSWC4jRzteS7lqizT47Nv_yH05aIl9NoJ2QLgyKTzoYA-YRivluR-SxIWjaxVvIfzt0alBIyAC_tQyqBmPac3F79oirFRtNHLTbECGcz3GrDIB1wfr1WgQdb3RXUY7hLRUo4W9O2S_PqqinYeBALenTz5e4eekjtAZX004mNsn3SWi5V5BnRxqXpkW0wFPOMRw-f4Y4_sHByenl_0qg8wvWqF-AnLQm9F |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKcoALory6UKhBIOCQdhM7dnJAaGmpunTbImirvQU7tttKJVmaXUH_FL-RmbxoUAVceolW8djZjMfjb5x5EPJcx4M4dZx5mqnYA-0nPGXgYqNQSmlMqh1GI-_siq0D_mESThbIzyYWBt0qG51YKmqTp3hGvgZWUwgmFCzNt9NvHlaNwq-rTQmNSiy27fl3MNmKN6MNmN8XQbD5fn99y6urCnipiIOZZ0ygfB7YIBXGRKESilsVSu0Moh1nRKRDI7XgERA6QDtCKxeljBtfcV8qBuNeI9c5nozD-pGT1sAD3SFEHZ7HpL9WS8PqNM_sKiaCGWAxtwvbX1kloN0LetPTvLgM6P7pr3lhA9y8TW7VyJUOK1FbJAs2u0MWa91Q0Fd1AuvXd8mPjwDJvyo6xAoQ07xMBXGS0TH6JxUwgKWNUFhD8SCYrjdOTBTB77ygKjN0w2LYpqXQVdE6kGV2Dr-OwWSguaN7WGGcjtqQsuIeObiSubhPehlwd4nQyFdOq9CaCAALxhtxkyowlgZWAyiOXZ-whvFJWqc_xyocp0n5TU-CGVTxMcHpSurp6hOv7TWt0n_8g_4dzmlLi8m7yxv52VFS64JEWt9Z3_IoiPHlYxUxxZ3WgJWc44r1yQpKRFJFwrYqKBlyCfIfMsH75FlJgQk8MvQQOlLzokhGe4f_QfT5U4foZU3kcmBHquqoDHgnTAzWoVzuUIIaSjvNSyi_DVeK5PeChZ6NTF_e_LRtxkHR6y-z-RxosIIs80UAfH1QLYGWs0EgS_O6T2RncXRY323JTo7L_OmMSXh2_PDvf2uF3Nja3xkn49Hu9iNyE4BygC6Cvr9MerOzuX0MYHSmn5QagJIvV61yfgFfW6EK |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGkRAviPG1wmAGgYCHbE3sxMkDQmWlWtnYJmCob8GO7W3SSMrSCvav8ddxlzhhQRPwspeqqs9Oc747_y65D0KeqmSQZJYzTzGZeGD9Ik9q-DBxKITQOlMWs5Hf70ZbB_zdNJwukZ9NLgyGVTY2sTLUusjwGfkGeE0huFAYhWNdWMT-aPx69s3DDlL4prVpp1GLyLY5-w7uW_lqMoK9fhYE47efNrc812HAy6IkmHtaB9LngQmySOs4lJHkRoZCWY3Ix-ooVqEWKuIxEFpAPpGSNs4Y177kvpAM1r1CrgoGqAp0SUxbZw_sSBS5VD0m_A0nGeuzIjfrWBRmgI3dzh2FVceA9lzozU6K8iLQ-2fs5rnDcHyT3HAolg5rsVsmSya_RZadnSjpC1fM-uVt8mMf4PlXSYfYDWJWVGUhjnO6g7FKJSxgaCMgRlN8KEw3m4AmikB4UVKZazoymMJpKEyV1CW1zM_g2xG4D7SwdA-7jdNJm15W3iEHl7IXd0kvB-6uEBr70ioZGh0DeMHcI64zCY7TwCgAyIntE9YwPs1cKXTsyHGSVu_3BLhENR9T3K7UbVefeO2sWV0K5B_0b3BPW1os5F39UJweps4upML41viGx0GCN5_ImElulQLcZC2XrE_WUCLSOiu2NUfpkAvQhZBFvE-eVBRYzCNHtTiUi7JMJ3uf_4Po44cO0XNHZAtgRyZdhgbcExYJ61CudijBJGWd4RWU34YrZfpbeWFmI9MXDz9uh3FRjADMTbEAGuwmy_woAL7eq1Wg5WwQiMrV7hPRUY4O67sj-fFRVUudMQHXTu7__W-tkWtgbNKdye72A3IdMHOA0YK-v0p689OFeQi4dK4eVQaAki-XbXF-AfBJpUk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+Apolipoprotein+Levels+Are+Associated+with+Cognitive+Status+and+Decline+in+a+Community+Cohort+of+Older+Individuals&rft.jtitle=PloS+one&rft.au=Song%2C+Fei&rft.au=Poljak%2C+Anne&rft.au=Crawford%2C+John&rft.au=Kochan%2C+Nicole+A&rft.date=2012-06-11&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=7&rft.issue=6&rft.spage=e34078&rft_id=info:doi/10.1371%2Fjournal.pone.0034078&rft.externalDocID=A477115364 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |